Results 131 to 140 of about 38,611 (262)

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, Volume 13, Issue 20, 9 April 2026.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

A deceptively benign biliary lesion revealing an ALK‐rearranged intrahepatic cholangiocarcinoma

Histopathology, EarlyView.
Anne‐Cécile Brunac, Marie Danjoux, Hadrien Reboul, Ronan Guillemin, Fabrice Muscari, Janick Selves   +5 more
wiley   +1 more source

Cancer‐Associated Fibroblasts Functions as Multifunctional Architects of the Tumor Stroma and Represent Emerging Therapeutic Vulnerabilities

Advanced Science, Volume 13, Issue 24, 27 April 2026.
ABSTRACT Cancer‐associated fibroblasts (CAFs) are the predominant stromal components within the tumor microenvironment (TME), playing multifaceted roles in cancer progression through dynamic interactions with neoplastic and immune cells. Emerging evidence has revealed remarkable heterogeneity and plasticity of CAFs, which originate from diverse ...
Rujiao Liu, Lili Su, Shuiping Gao, Wenting Liu, Hongxia Wang   +4 more
wiley   +1 more source

Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy

Advanced Science, Volume 13, Issue 22, 17 April 2026.
Leveraging 3D bioprinting, this study establishes patient‐derived in vitro models of intrahepatic cholangiocarcinoma. These models faithfully recapitulate the histopathology, molecular profiles, and genomic characteristics of the original patient tumors.
Yuce Lu, Liwei Du, Minghao Sun, Kai Zhang, Mingchang Pang, Shangze Jiang, Jiaxun Dong, Xiyue Liu, Bao Jin, Fu Xu, Hang Sun, Jiangang Zhang, Huiyu Yang, Xiaobo Yang, Xin Lu, Yiyao Xu, Haitao Zhao, Shunda Du, Xinting Sang, Yongchang Zheng, Lei Zhang, Xueshuai Wan, Huayu Yang, Yilei Mao   +23 more
wiley   +1 more source

Case report: Combinations of immune checkpoint inhibitor, chemotherapy, and hyperthermia therapy avoid lymphatic recurrence in cholangiocarcinoma

Frontiers in Oncology
Cholangiocarcinoma is a malignancy known for its aggressiveness and limited treatment options. The malignant tumor behaviors include intrahepatic recurrence, regional lymph node (LN) metastasis, peritoneal carcinomatosis, and lung metastasis.
Heng-Jui Chang, Chiao-Hsu Ke, Yu-Shan Wang, Yu-Shan Wang   +3 more
doaj   +1 more source

Advances in Artificial Intelligence‐Based Liver‐Related Semantic Segmentation Techniques and Applications Using CT Imaging

Cancer Medicine, Volume 15, Issue 4, April 2026.
This review summarizes clinical and technical advancements in AI‐based semantic segmentation for liver organ, tumors, and vasculature on CT imaging. It highlights key applications in surgical planning and disease evaluation while discussing critical challenges and strategies for real‐world clinical deployment and multimodal integration.
Jun Pu, Xuan Wang, Liang Zhu, Jie Pan
wiley   +1 more source

Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
A phase II single‐center prospective study evaluating envafolimab combined with capecitabine and lenvatinib as postoperative adjuvant therapy in resected biliary tract cancer with high‐risk recurrence factors. The regimen demonstrated encouraging efficacy (median DFS 15.6 months; 1‐year DFS 68.3%; 1‐year OS 91.4%) and manageable safety, with no ...
Yitong Tian, Tian Lei, Qingyang Ruan, Xueying Zhou, Ruijing Shen, Tianao Xie, Shijie Li, Xiujun Cai, Mingyu Chen   +8 more
wiley   +1 more source

Longitudinal Monitoring of GRIm and HCC‐GRIm Scores Reveals Immunologically Relevant Prognostic Indicators in Hepatocellular Carcinoma Undergoing TACE Plus ICIs and Anti‐VEGF Antibodies/TKIs

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objective To investigate the clinical significance and peripheral immunological basis underlying the dynamic changes of Gustave Roussy Immune (GRIm) score and the hepatocellular carcinoma‐specific GRIm (HCC‐GRIm) score in unresectable hepatocellular carcinoma (uHCC) patients treated with transarterial chemoembolization (TACE) combined with ...
Lihao Qin, Linzhou Zhu, Yu Wang, Wanci Li, Shuai Zhang, Jian Shen, Xiaoli Zhu   +6 more
wiley   +1 more source

Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
Improvement in progression‐free survival, overall survival and objective response rate for ivosidenib‐treated patients compared to non‐treated patients across 317 patients in a systematic review and meta‐analysis. Abstract Background Cholangiocarcinoma (CCA) is the second most common liver malignancy after hepatocellular carcinoma and is difficult to ...
Lindsay Wong, Chisom Nwosu, Denise Nadora, Jimmy Wen, Akash Pathak, Eldo Frezza, Wei Tse Li   +6 more
wiley   +1 more source

Spatial omics for profiling the dynamic tumor microenvironment

Clinical &Translational Immunology, Volume 15, Issue 4, 2026.
Spatially resolved transcriptomics and proteomics map RNA/protein in intact tumor tissues, revealing crucial cancer–immune interactions across the different stages of tumor evolution. Integrating AI promises translational impact, but gaps in cross‐platform integration, standards, compute, validation and interpretability remain.
Hao Nguyen, Merrin Mary Eapen, Quan Nguyen, Ankur Sharma   +3 more
wiley   +1 more source